Previous 10 | Next 10 |
RP1 : Updated deep and durable response data with Opdivo ® in CSCC and anti- PD1 failed melanoma continue to support ongoing registration-directed development RP2 : Single agent d eep and durable responses in ...
Replimune Group (REPL) has priced public offering of 4,687,500 common shares at $40/share, for gross proceeds of ~$250M.The company also priced public offering of pre-funded warrants to purchase 1,562,500 common shares at $39.9999 per pre-funded warrant.Underwriters' over-allotment is an addi...
Replimune (REPL) has proposed public offering of $125M of common stock. Underwriters have an option to purchase up to an additional $18.75M sharesOffer price and number of shares is yet to be determined. For further details see: Replimune readies $125M equity offering
WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of No...
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
Shares of Replimune Group (NASDAQ: REPL) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The big jump resulted from the company's announcement that it will present encouraging data from two early-stage clinical studies eva...
Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cycl...
Gainers: Interpace Biosciences (IDXG) +41%.Allscripts Healthcare Solutions (MDRX) +31%.Replimune Group (REPL) +27%.VOXX International (VOXX) +25%.AnaptysBio (ANAB) +22%.NIO (NIO) +20%.OncoCyte (OCX) +20%.Panhandle Oil and Gas (PHX) +16%.RealNetworks (RNWK) +14%.Oblong (OBLG) +13%.Losers:...
I nitial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® ( nivolumab ) in patients with solid tumors An u pdate from the m...
Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, So...
News, Short Squeeze, Breakout and More Instantly...
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Gold...
2024-06-07 07:00:05 ET Robert Burns from H.C. Wainwright issued a price target of $17.00 for REPL on 2024-06-07 06:07:00. The adjusted price target was set to $17.00. At the time of the announcement, REPL was trading at $7.11. The overall price target consensus is at $26...